Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4CNS 1

Conditions

Brain Neoplasms 290Glioblastoma 260Glioma 202Neuroblastoma 88Neoplasms 62Astrocytoma 56Central Nervous System Neoplasms 54Medulloblastoma 48Breast Neoplasms 44Melanoma 40Sarcoma 39Meningioma 39Neurofibromatosis 1 38Carcinoma, Non-Small-Cell Lung 38Lung Neoplasms 37Ependymoma 36Osteosarcoma 31Rhabdomyosarcoma 30Neoplasm Metastasis 28Sarcoma, Ewing 27Rhabdoid Tumor 27Diffuse Intrinsic Pontine Glioma 27Recurrence 26Oligodendroglioma 23Gliosarcoma 22Wilms Tumor 21Pancreatic Neoplasms 21Pheochromocytoma 20Hepatoblastoma 20Neurofibroma, Plexiform 19

Interventions

pertuzumab 1atezolizumab 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Metastatic Breast Cancer × CNS × 90 days × Clear all
NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡